Quantcast

Latest Rosiglitazone Stories

2009-03-26 08:00:00

ST. PAUL, Minn., March 26 /PRNewswire/ -- Pharmacy benefit manager Prime Therapeutics (Prime) announced that three of its clinical pharmacists, Patrick Gleason, PharmD, FCCP, BCPS, Cathy Starner, PharmD and Jeremy Schafer, PharmD were awarded the Journal of Managed Care Pharmacy (JMCP) Award of Excellence for their manuscript assessing rosiglitazone and pioglitazone utilization trends and associated medical and pharmacy claims data indicating risk for an adverse cardiovascular event. Prime's...

2009-02-24 05:00:00

NEW YORK, Feb. 24 /PRNewswire/ -- Mindset BioPharmaceuticals (USA) Inc ("MINDSET") a company privately held by MPM Capital and other shareholders announced today that it has received a Notice of Allowance in Europe related to patent applications describing the use of insulin sensitizer drugs for the prevention and treatment of memory loss. Drugs of this type include Rosiglitazone and Pioglitazone which have been approved for the treatment of type II diabetes mellitus. Glucose is used by...

2009-01-21 08:00:00

Basis Established for DNA-Guided Decision Support in Diabetes Drug Therapy HARTFORD, Conn., Jan. 21 /PRNewswire/ -- Research by Genomas has shown statistically significant associations of certain genes in vascular and energy pathways to body mass index (BMI) and edema (fluid retention) in patients taking the thiazolidinedione (TZD) drugs pioglitazone and rosiglitazone. The study, co-authored with investigators from Joslin Diabetes Center Affiliate at The Hospital of Central Connecticut,...

2009-01-08 14:10:00

LOS ALTOS, Calif., Jan. 8 /PRNewswire/ -- InteKrin Therapeutics, Inc., will present at the 27th Annual JP Morgan Global Healthcare Conference at 9:00 a.m. Pacific Time on Tuesday, January 13, 2009, to be held at the Westin St. Francis in San Francisco, California. InteKrin Therapeutics' President and CEO Denny Lanfear will present at the conference. About InteKrin (http://www.InteKrin.com): InteKrin Therapeutics is a privately-held clinical stage biopharmaceutical company...

986a558158ef4592eeff82e60a9c12d91
2008-12-10 14:20:00

A study released on Wednesday shows that long-term use of GlaxoSmithKline's Avandia and Takeda's Actos doubles the risk of bone fractures in women with type 2 diabetes. The two thiazolidinedione (TZD) drugs for diabetes were known for some time to be associated with fractures, but the magnitude of the risk had not been evaluated until now. "Women with type 2 diabetes are already at an increased risk of fractures, so any additional risk from thiazolidinedione therapy could have a considerable...

2008-12-04 08:13:31

A medication for diabetics may do more harm than good. Doctors are concerned rosiglitazone may increase older patients' risk of death and heart failure.A black box warning was recently added to two drugs, rosiglitazone and pioglitazone hydrochloride, cautioning patients with heart failure against using them. Recent studies have shown the risks linked to rosiglitazone are even greater than those associated with pioglitazone.Researchers at Brigham and Women's Hospital and Harvard Medical School...

a7fe3f28bdf764e7b102c35b2d8d45c81
2008-11-13 09:05:00

New findings support the claim that a controversial diabetes pill failed to significantly slow plaque buildup in heart arteries compared with an older drug. Since May of last year, Avandia, once a blockbuster drug made by British-based GlaxoSmithKline PLC, has been under a dark cloud of doubt. That's because a medical journal report suggested it could raise the risk of heart attacks and heart-related deaths; the American Diabetes Association recently said patients should avoid using it...

fdb89ddb7463ca2d19cb071d800f784a1
2008-10-31 10:30:00

Public Citizen, a consumer advocate group, has called on the U.S. to ban sales and distribution of the diabetes drug Avandia due to certain risks found to be linked with the drug. New research released by Public Citizen about the drug, used to treat Type 2 diabetes, comes as a working group with representatives from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes, unanimously advised against using Avandia, whose generic name is rosiglitazone,...

2008-10-30 21:00:11

PHILADELPHIA, Oct. 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline today issued the following response to a petition filed by Public Citizen to the U.S. Food and Drug Administration (FDA) on AVANDIA(R) (rosiglitazone maleate), a highly effective therapy for treating type 2 diabetes when used in the appropriate patient population. The safety of patients using our medicine is very important to us. On a continual basis, an external Hepatic Safety Board reviews any adverse event report received...

4c3eb47c3955711dbdd964a2c153b62d1
2008-10-28 08:40:00

Treatment for diabetic Americans has doubled in cost during the past six years. Last year, the bill hit an eye-popping $12.5 billion.Researchers said new, pricey drugs are driving the increase, despite a lack of evidence for the new drugs' greater benefits and safety. The study follows updated treatment advice for Type 2 diabetes that was issued last week.In the recommendations, an expert panel told doctors to use older, cheaper drugs first.Another study points to evidence that metformin, an...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.